Joseph A. Kendra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Joseph A. Kendra has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Gabriel Ignacio Parra
Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA
10 shared publications - Kentaro Tohma
Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration
8 shared publications - Lauren A. Ford Siltz
Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration
6 shared publications - Kelsey A. Pilewski
Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration
3 shared publications - Michael Landivar
Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration
3 shared publications Yamei Gao
Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, USA
3 shared publications
Latest Publications
- Open Access
- 3 July 2026
- Published by Microbiology Society in Journal of General Virology
- Vol. 107 (7)
Probing the sequence constraints for the stable incorporation of chimeric NSP1 segments into infectious rotaviruses
Rotaviruses are a global cause of acute paediatric gastroenteritis. They present a genome of 11 dsRNA segments that have been successfully incorporated into a plasmid-based reverse-genetics system that enables the generation of reassortant and chimeric viruses as a possible foundation for multi-virus vaccines. Studies have shown that these chimeric segments are pruned across successive passages, highlighting a need to better define the constraints that govern segment recognition and stable incorporation into mature viruses. This work leveraged the reverse-genetics system to investigate these constraints by introducing a series of modifications to a chimeric NSP1 sequence with an internally cloned GFP insert (NSP1gfp). Across ten serial passages, a pruned NSP1gfp segment emerged and eventually outcompeted the original construct, resulting in a loss of GFP expression. The removal of the entire NSP1 ORF sequence 3′ of the insert resulted in prolonged GFP expression, but closer examination of rotavirus RNA suggested that these modifications were merely delaying replacement from pruned segments, rather than avoiding their emergence. A series of systematic truncations to the remaining NSP1 ORF sequence 5′ of the GFP insert showed that as little as 27 nt of the original coding sequence is needed for rescue of infectious chimeric rotavirus. Despite a near-total replacement of NSP1 with GFP, pruned segments emerged and were preferentially incorporated into later passages, which was correlated with increased infectivity at the expense of GFP expression. These results suggest that factors beyond excess segment size drive pruning of chimeric sequences. Closer sequence analysis of pruned segments revealed that pruning occurred at high GC regions of the insert, suggesting an inherent incompatibility with the genome composition of rotavirus segments. These findings shed light on the requirements for rotavirus segment recognition and stability, as well as provide important considerations for the usage of this model as a potential vaccine platform.
- 3 July 2026
- Published by Microbiology Society in Journal of General Virology
- Vol. 107 (7)
Open AccessProbing the sequence constraints for the stable incorporation of chimeric NSP1 segments into infectious rotaviruses
Rotaviruses are a global cause of acute paediatric gastroenteritis. They present a genome of 11 dsRNA segments that have been successfully incorporated into a plasmid-based reverse-genetics system that enables the generation of reassortant and chimeric viruses as a possible foundation for multi-virus vaccines. Studies have shown that these chimeric segments are pruned across successive passages, highlighting a need to better define the constraints that govern segment recognition and stable incorporation into mature viruses. This work leveraged the reverse-genetics system to investigate these constraints by introducing a series of modifications to a chimeric NSP1 sequence with an internally cloned GFP insert (NSP1gfp). Across ten serial passages, a pruned NSP1gfp segment emerged and eventually outcompeted the original construct, resulting in a loss of GFP expression. The removal of the entire NSP1 ORF sequence 3′ of the insert resulted in prolonged GFP expression, but closer examination of rotavirus RNA suggested that these modifications were merely delaying replacement from pruned segments, rather than avoiding their emergence. A series of systematic truncations to the remaining NSP1 ORF sequence 5′ of the GFP insert showed that as little as 27 nt of the original coding sequence is needed for rescue of infectious chimeric rotavirus. Despite a near-total replacement of NSP1 with GFP, pruned segments emerged and were preferentially incorporated into later passages, which was correlated with increased infectivity at the expense of GFP expression. These results suggest that factors beyond excess segment size drive pruning of chimeric sequences. Closer sequence analysis of pruned segments revealed that pruning occurred at high GC regions of the insert, suggesting an inherent incompatibility with the genome composition of rotavirus segments. These findings shed light on the requirements for rotavirus segment recognition and stability, as well as provide important considerations for the usage of this model as a potential vaccine platform.
- Open Access
- 17 February 2026
- Published by American Society for Microbiology in Journal of Virology
- Vol. 100 (2) , e0180425
Variable and conserved B cell epitopes of GII.4 human noroviruses
Norovirus is a leading cause of acute gastroenteritis worldwide, imposing a major burden on public health and healthcare systems. Despite its significant medical impact, no licensed vaccines or specific antiviral therapies are currently available. Norovirus vaccine development is complicated by several factors, including the extreme genetic and antigenic diversity. In particular, the predominant genotype GII.4 exhibits a continuous emergence of novel variants that can evade immune responses acquired from previous infections. In this manuscript, we will summarize the characteristics and current knowledge of the B cell responses elicited by conserved and variable GII.4 epitopes and discuss how these findings inform our understanding of responses to other pandemic norovirus genotypes. We also highlight how ongoing research in this area may provide critical insights for the development of broadly protective norovirus vaccines.
- 17 February 2026
- Published by American Society for Microbiology in Journal of Virology
- Vol. 100 (2) , e0180425
Open AccessVariable and conserved B cell epitopes of GII.4 human noroviruses
Norovirus is a leading cause of acute gastroenteritis worldwide, imposing a major burden on public health and healthcare systems. Despite its significant medical impact, no licensed vaccines or specific antiviral therapies are currently available. Norovirus vaccine development is complicated by several factors, including the extreme genetic and antigenic diversity. In particular, the predominant genotype GII.4 exhibits a continuous emergence of novel variants that can evade immune responses acquired from previous infections. In this manuscript, we will summarize the characteristics and current knowledge of the B cell responses elicited by conserved and variable GII.4 epitopes and discuss how these findings inform our understanding of responses to other pandemic norovirus genotypes. We also highlight how ongoing research in this area may provide critical insights for the development of broadly protective norovirus vaccines.
- Top Cited PapersOpen Access
- 24 November 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1)
GII.17 norovirus re-emerged in the 2020s as a result of dynamic and adaptive evolutionary processes
Over the past two years, increased norovirus activity has been reported in multiple countries, accompanied by a rise in genotype GII.17 prevalence. Despite causing large outbreaks in Asia during 2014-2016, GII.17 has not historically been considered a predominant genotype. In this study, using 1471 archival and newly-identified GII.17 genomes, we investigated (i) global diversification patterns of this virus at the whole-genome level, (ii) in-depth mutational patterns within 511 viruses detected during a 10-year national survey in Germany, and (iii) intra-host viral diversity and adaptation processes that lead to the predominance of the GII.17 virus. The recent GII.17 norovirus exhibited extensive genetic diversity and multiple back-and-forth and recurrent mutations during the early phase of its epidemic; however, this diversity declined by 2024, suggesting that the virus had reached a phenotype efficient for human infection. Experimental data confirmed that mutations in the viral capsid enhanced binding to host factors associated with virus entry and resulted in antigenic changes compared to previously circulating clusters. Overall, this study demonstrated that the recent surge of GII.17 resulted from a dynamic, multifaceted process involving diverse adaptive strategies, ultimately enabling the virus to achieve sustained transmission within the human population.
- 24 November 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1)
Top Cited PapersOpen AccessGII.17 norovirus re-emerged in the 2020s as a result of dynamic and adaptive evolutionary processes
Over the past two years, increased norovirus activity has been reported in multiple countries, accompanied by a rise in genotype GII.17 prevalence. Despite causing large outbreaks in Asia during 2014-2016, GII.17 has not historically been considered a predominant genotype. In this study, using 1471 archival and newly-identified GII.17 genomes, we investigated (i) global diversification patterns of this virus at the whole-genome level, (ii) in-depth mutational patterns within 511 viruses detected during a 10-year national survey in Germany, and (iii) intra-host viral diversity and adaptation processes that lead to the predominance of the GII.17 virus. The recent GII.17 norovirus exhibited extensive genetic diversity and multiple back-and-forth and recurrent mutations during the early phase of its epidemic; however, this diversity declined by 2024, suggesting that the virus had reached a phenotype efficient for human infection. Experimental data confirmed that mutations in the viral capsid enhanced binding to host factors associated with virus entry and resulted in antigenic changes compared to previously circulating clusters. Overall, this study demonstrated that the recent surge of GII.17 resulted from a dynamic, multifaceted process involving diverse adaptive strategies, ultimately enabling the virus to achieve sustained transmission within the human population.
- Open Access
- 7 October 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (40)
Functional diversity in GII.4 norovirus entry: HBGA binding and capsid clustering dynamics
Human noroviruses (HuNoVs), especially GII.4 strains, are the leading cause of acute viral gastroenteritis worldwide, yet no approved vaccines or antivirals exist. The pandemic GII.4 Sydney 2012 strain enters cells via membrane wounding and clathrin-independent carrier-mediated endocytosis, but it is unclear whether this entry mechanism is conserved across GII.4 variants. We compared early binding and entry of multiple GII.4 variants using wild-type and mutant GII.4 virus-like particles (VLPs) and modified human intestinal enteroid cultures. Only a subset of GII.4 variants, including GII.4 Sydney, form distinct, histo-blood group antigen (HBGA)-dependent capsid clusters on the cell surface. Clustering strains display significantly enhanced membrane wounding and endocytosis compared to nonclustering strains and outcompete nonclustering strains in replication assays exhibited by complete inhibition of GII.4 Sydney replication. Using mutant VLPs and an HBGA nonbinding mutant (R345A), we identified two residues, V333 and R339, in the VP1 protruding domain as critical mediators of clustering and entry. Mutations of these residues disrupt clustering and endocytosis without affecting HBGA binding, suggesting a role in postattachment processes. While clustering and endocytosis are contingent upon VLP binding to HBGAs, inhibitor studies show they are independent of host protein glycosylation and are driven by lipid raft remodeling regulated by cholesterol and ceramides. Quantitative analyses across multiple GII.4 variants reveal an apparent dichotomy between clustering and nonclustering phenotypes, with clustering variants exhibiting higher entry competence. This distinction offers insight into strain-specific cell entry mechanisms and may aid in identifying the elusive proteinaceous HuNoV cellular receptor(s) supporting targeted therapeutic development.
- 7 October 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (40)
Open AccessFunctional diversity in GII.4 norovirus entry: HBGA binding and capsid clustering dynamics
Human noroviruses (HuNoVs), especially GII.4 strains, are the leading cause of acute viral gastroenteritis worldwide, yet no approved vaccines or antivirals exist. The pandemic GII.4 Sydney 2012 strain enters cells via membrane wounding and clathrin-independent carrier-mediated endocytosis, but it is unclear whether this entry mechanism is conserved across GII.4 variants. We compared early binding and entry of multiple GII.4 variants using wild-type and mutant GII.4 virus-like particles (VLPs) and modified human intestinal enteroid cultures. Only a subset of GII.4 variants, including GII.4 Sydney, form distinct, histo-blood group antigen (HBGA)-dependent capsid clusters on the cell surface. Clustering strains display significantly enhanced membrane wounding and endocytosis compared to nonclustering strains and outcompete nonclustering strains in replication assays exhibited by complete inhibition of GII.4 Sydney replication. Using mutant VLPs and an HBGA nonbinding mutant (R345A), we identified two residues, V333 and R339, in the VP1 protruding domain as critical mediators of clustering and entry. Mutations of these residues disrupt clustering and endocytosis without affecting HBGA binding, suggesting a role in postattachment processes. While clustering and endocytosis are contingent upon VLP binding to HBGAs, inhibitor studies show they are independent of host protein glycosylation and are driven by lipid raft remodeling regulated by cholesterol and ceramides. Quantitative analyses across multiple GII.4 variants reveal an apparent dichotomy between clustering and nonclustering phenotypes, with clustering variants exhibiting higher entry competence. This distinction offers insight into strain-specific cell entry mechanisms and may aid in identifying the elusive proteinaceous HuNoV cellular receptor(s) supporting targeted therapeutic development.
- Open Access
- 22 July 2025
- Published by American Society for Microbiology in Journal of Virology
- Vol. 99 (7) , e0061125
Manipulation of immunodominant variable epitopes of norovirus capsid protein elicited cross-blocking antibodies to different GII.4 variants despite the low potency of the polyclonal sera
Norovirus is a major cause of viral acute gastroenteritis. The predominant genotype, GII.4, presents a continuous emergence of new variants that could escape immunity developed in previous infections. The emergence of GII.4 variants is associated with multiple mutations on five antigenic sites (A, C, D, E, and G) of the major viral capsid protein. Antigenic site A includes most immunodominant epitopes, while antigenic site G shifted its immunodominance during the evolution of GII.4 noroviruses. This interrelation of immunodominance and high variability challenges the development of universal vaccines for GII.4 noroviruses. In this study, we designed an immunogen that aims to elicit antibodies toward conserved regions by mutating epitopes from antigenic sites A and G. Immunization of mice with mutant virus-like particles (VLPs) in which antigenic sites A and G were resurfaced with alanine mutations (12∆AG) elicited multiple cross-blockade monoclonal antibodies against different GII.4 variants. However, the carbohydrate-blockade titers at the serum level were low as compared with wild-type VLPs as the result of low frequency and/or low potency of these cross-blockade antibodies. This study confirmed that cross-reactive antibodies can be elicited by mutating highly variable epitopes, but further studies are required to overcome the low immunogenicity of these conserved epitopes for the development of vaccine candidates that could elicit broadly protective responses. IMPORTANCE: The fast-evolving nature of RNA viruses is a major obstacle for vaccine design and development. Protective antibodies are often directed to highly variable sites, so viruses could rapidly escape from immunity acquired from previous infections or vaccination. Here, we designed mutant norovirus virus-like particles (VLPs) in which the immunodominant and highly variable epitopes were resurfaced into alanine for refocusing immune responses toward conserved epitopes. The mutant VLPs could elicit multiple broadly cross-reactive antibodies against different GII.4 noroviruses that emerged in the 1970s–2010s; however, the frequency of these cross-reactive antibodies was low at the serum level. While further investigations are required to enhance the potency of these cross-reactive responses, this study opens a new avenue for the rational development of efficacious norovirus vaccines.
- 22 July 2025
- Published by American Society for Microbiology in Journal of Virology
- Vol. 99 (7) , e0061125
Open AccessManipulation of immunodominant variable epitopes of norovirus capsid protein elicited cross-blocking antibodies to different GII.4 variants despite the low potency of the polyclonal sera
Norovirus is a major cause of viral acute gastroenteritis. The predominant genotype, GII.4, presents a continuous emergence of new variants that could escape immunity developed in previous infections. The emergence of GII.4 variants is associated with multiple mutations on five antigenic sites (A, C, D, E, and G) of the major viral capsid protein. Antigenic site A includes most immunodominant epitopes, while antigenic site G shifted its immunodominance during the evolution of GII.4 noroviruses. This interrelation of immunodominance and high variability challenges the development of universal vaccines for GII.4 noroviruses. In this study, we designed an immunogen that aims to elicit antibodies toward conserved regions by mutating epitopes from antigenic sites A and G. Immunization of mice with mutant virus-like particles (VLPs) in which antigenic sites A and G were resurfaced with alanine mutations (12∆AG) elicited multiple cross-blockade monoclonal antibodies against different GII.4 variants. However, the carbohydrate-blockade titers at the serum level were low as compared with wild-type VLPs as the result of low frequency and/or low potency of these cross-blockade antibodies. This study confirmed that cross-reactive antibodies can be elicited by mutating highly variable epitopes, but further studies are required to overcome the low immunogenicity of these conserved epitopes for the development of vaccine candidates that could elicit broadly protective responses. IMPORTANCE: The fast-evolving nature of RNA viruses is a major obstacle for vaccine design and development. Protective antibodies are often directed to highly variable sites, so viruses could rapidly escape from immunity acquired from previous infections or vaccination. Here, we designed mutant norovirus virus-like particles (VLPs) in which the immunodominant and highly variable epitopes were resurfaced into alanine for refocusing immune responses toward conserved epitopes. The mutant VLPs could elicit multiple broadly cross-reactive antibodies against different GII.4 noroviruses that emerged in the 1970s–2010s; however, the frequency of these cross-reactive antibodies was low at the serum level. While further investigations are required to enhance the potency of these cross-reactive responses, this study opens a new avenue for the rational development of efficacious norovirus vaccines.
- Open Access
- 22 July 2025
- Published by American Society for Microbiology in Journal of Virology
- Vol. 99 (7) , e0065225
Highly variable antigenic site located at the apex of GII.4 norovirus capsid protein induces cross-reactive blocking antibodies in a variant-specific manner
GII.4 norovirus is responsible for most cases of viral gastroenteritis worldwide. The complex epidemiology and extreme GII.4 antigenic diversity could challenge the development of a vaccine. Most antibody responses to GII.4 norovirus target five antigenic sites mapping to the major viral capsid, whose variability has been associated with the emergence of antigenically distinct variants. Bioinformatics analyses of amino acid sequences from these antigenic sites demonstrated that antigenic site A is the most variable and relevant site for antigenic diversification. Despite this complex diversity, cross-blocking was demonstrated in the profiling of site A-mapping mouse monoclonal antibodies generated against two antigenically distinct GII.4 variants. Using a novel immunoassay, we determined the contribution of specific epitopes to blockade function in polyclonal sera and observed extensive cross-blocking in which 36% was attributed to antibodies mapping to antigenic site A. However, cross-reactivity was virus-dependent, with the greatest breadth exhibited by contemporary variants that emerged after 2006. Notably, cross-blocking titers associated with antibodies mapping to antigenic site A are differentially affected by an increasing number of mutations on the capsid. Since the elicitation of blocking antibodies to conserved regions of the GII.4 norovirus capsid is infrequent, a better understanding of how to elicit cross-protective responses to immunodominant variable antigenic sites could guide norovirus vaccine development. IMPORTANCE: GII.4 noroviruses exhibit an accumulation of mutations on their capsid protein, leading to the continuous emergence and turnover of new variants that can escape herd immunity. Despite the fact that most antibodies mapping to the variable antigenic sites of GII.4 norovirus show exquisite specificity, cross-neutralizing antibodies mapping to these variable sites have also been described. In this study, we systematically evaluate the antigenicity of a panel of different GII.4 antigens to demonstrate that cross-reactive responses are elicited in a virus-dependent manner in naïve mice. Notably, one wild-type virus demonstrated multiple instances of potent cross-blocking responses, providing new hopes for the development of cross-protective vaccines against human norovirus.
- 22 July 2025
- Published by American Society for Microbiology in Journal of Virology
- Vol. 99 (7) , e0065225
Open AccessHighly variable antigenic site located at the apex of GII.4 norovirus capsid protein induces cross-reactive blocking antibodies in a variant-specific manner
GII.4 norovirus is responsible for most cases of viral gastroenteritis worldwide. The complex epidemiology and extreme GII.4 antigenic diversity could challenge the development of a vaccine. Most antibody responses to GII.4 norovirus target five antigenic sites mapping to the major viral capsid, whose variability has been associated with the emergence of antigenically distinct variants. Bioinformatics analyses of amino acid sequences from these antigenic sites demonstrated that antigenic site A is the most variable and relevant site for antigenic diversification. Despite this complex diversity, cross-blocking was demonstrated in the profiling of site A-mapping mouse monoclonal antibodies generated against two antigenically distinct GII.4 variants. Using a novel immunoassay, we determined the contribution of specific epitopes to blockade function in polyclonal sera and observed extensive cross-blocking in which 36% was attributed to antibodies mapping to antigenic site A. However, cross-reactivity was virus-dependent, with the greatest breadth exhibited by contemporary variants that emerged after 2006. Notably, cross-blocking titers associated with antibodies mapping to antigenic site A are differentially affected by an increasing number of mutations on the capsid. Since the elicitation of blocking antibodies to conserved regions of the GII.4 norovirus capsid is infrequent, a better understanding of how to elicit cross-protective responses to immunodominant variable antigenic sites could guide norovirus vaccine development. IMPORTANCE: GII.4 noroviruses exhibit an accumulation of mutations on their capsid protein, leading to the continuous emergence and turnover of new variants that can escape herd immunity. Despite the fact that most antibodies mapping to the variable antigenic sites of GII.4 norovirus show exquisite specificity, cross-neutralizing antibodies mapping to these variable sites have also been described. In this study, we systematically evaluate the antigenicity of a panel of different GII.4 antigens to demonstrate that cross-reactive responses are elicited in a virus-dependent manner in naïve mice. Notably, one wild-type virus demonstrated multiple instances of potent cross-blocking responses, providing new hopes for the development of cross-protective vaccines against human norovirus.
- 5 December 2024
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 12 (12) , e0114324
Characterization of cross-reactive, non-neutralizing monoclonal antibodies against a pandemic GII.4 norovirus variant
Antibodies are thought to play a major role in protection against human norovirus infection. Mouse humoral responses closely mimic those of humans; thus, mouse models are used to characterize norovirus epitopes on the major viral capsid protein, VP1. We have developed a panel of mouse monoclonal antibodies (mAbs) produced against the last pandemic variant to emerge, Sydney 2012. While most mAbs (25/44) were mapped to variable antigenic sites on VP1, 19 of the mAbs were cross-reactive against multiple genotypes or GII.4 variants. Most (12/19) of the cross-reactive mAbs bound to the Shell domain and were cross-reactive with different GII noroviruses. Interestingly, mAb 30A11 exhibited cross-reactivity against all tested norovirus genotypes (GI, GII, GIV, and GIX). This mAb was mapped to a highly conserved region of the Shell domain ( 51 PIDPWII 57 ) using peptide ELISA and immunofluorescence. Of those mapping to the Protruding (P) domain, two (19C10 and 14B11) showed cross-reactivity with GII noroviruses. Using hydrogen-deuterium exchange mass spectrometry, we mapped 19C10 to a conserved region of the P domain near the P/Shell interface, which explains its cross-reactivity with different GII noroviruses and lack of histo-blood group antigen-blocking activity. Binding and mutational analyses showed that residues 518, 519, and 525 are important for 19C10 and 14B11 epitope recognition. While the antibodies described here are mostly non-neutralizing, they can be useful tools for research and diagnostics of noroviruses. The role of non-neutralizing, cross-reactive antibodies targeting different areas of the viral capsid merits further research to facilitate our understanding of immunity to norovirus infection and disease. IMPORTANCE: To gain insights into the overall immune responses to human norovirus, we characterized non-neutralizing, cross-reactive monoclonal antibodies (mAbs) developed against a pandemic GII.4 norovirus. We determined the binding epitope of an antibody that exhibited cross-reactivity against all tested noroviruses, which makes it a useful tool for research and diagnostics. The epitope of two additional non-neutralizing mAbs was mapped to a less conserved region on the viral capsid protein, explaining their cross-reactivity patterns. Often overlooked, the role of non-neutralizing, cross-reactive mAbs merits further research to facilitate our understanding of immunity to norovirus infection and disease.
- 5 December 2024
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 12 (12) , e0114324
Characterization of cross-reactive, non-neutralizing monoclonal antibodies against a pandemic GII.4 norovirus variant
Antibodies are thought to play a major role in protection against human norovirus infection. Mouse humoral responses closely mimic those of humans; thus, mouse models are used to characterize norovirus epitopes on the major viral capsid protein, VP1. We have developed a panel of mouse monoclonal antibodies (mAbs) produced against the last pandemic variant to emerge, Sydney 2012. While most mAbs (25/44) were mapped to variable antigenic sites on VP1, 19 of the mAbs were cross-reactive against multiple genotypes or GII.4 variants. Most (12/19) of the cross-reactive mAbs bound to the Shell domain and were cross-reactive with different GII noroviruses. Interestingly, mAb 30A11 exhibited cross-reactivity against all tested norovirus genotypes (GI, GII, GIV, and GIX). This mAb was mapped to a highly conserved region of the Shell domain ( 51 PIDPWII 57 ) using peptide ELISA and immunofluorescence. Of those mapping to the Protruding (P) domain, two (19C10 and 14B11) showed cross-reactivity with GII noroviruses. Using hydrogen-deuterium exchange mass spectrometry, we mapped 19C10 to a conserved region of the P domain near the P/Shell interface, which explains its cross-reactivity with different GII noroviruses and lack of histo-blood group antigen-blocking activity. Binding and mutational analyses showed that residues 518, 519, and 525 are important for 19C10 and 14B11 epitope recognition. While the antibodies described here are mostly non-neutralizing, they can be useful tools for research and diagnostics of noroviruses. The role of non-neutralizing, cross-reactive antibodies targeting different areas of the viral capsid merits further research to facilitate our understanding of immunity to norovirus infection and disease. IMPORTANCE: To gain insights into the overall immune responses to human norovirus, we characterized non-neutralizing, cross-reactive monoclonal antibodies (mAbs) developed against a pandemic GII.4 norovirus. We determined the binding epitope of an antibody that exhibited cross-reactivity against all tested noroviruses, which makes it a useful tool for research and diagnostics. The epitope of two additional non-neutralizing mAbs was mapped to a less conserved region on the viral capsid protein, explaining their cross-reactivity patterns. Often overlooked, the role of non-neutralizing, cross-reactive mAbs merits further research to facilitate our understanding of immunity to norovirus infection and disease.
- Open Access
- 21 February 2024
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 230 (4) , 982-994
Analysis of Archival Sera From Norovirus-Infected Individuals Demonstrates That Cross-Blocking of Emerging Viruses Is Genotype-Specific
Background: Rapidly evolving RNA viruses, such as human norovirus, generate extraordinary sequence diversity, posing a significant challenge to vaccine design. This diversity, coupled with short-lasting natural immunity, leads to reinfection throughout one's lifetime. How reexposure shapes humoral immunity to future norovirus strains remains incompletely understood. Methods: We profiled the antibody responses following 2 community gastroenteritis outbreaks with GII.2 and GII.6 noroviruses in 1971. Using diverse virus-like particles (VLPs), enzyme-linked immunosorbent assay (ELISA), and carbohydrate-blocking assays (surrogate for neutralization), we examined the antibody response at acute and convalescent timepoints following GII.6 infection. Results: Convalescent sera displayed strong homologous blocking, demonstrating a 5-fold increase in GII.6 carbohydrate blockade over acute samples, and broad blocking of diverse archival and modern GII.6 noroviruses. Convalescent sera displayed limited carbohydrate blocking of heterotypic VLPs, despite high ELISA binding titers. Select individuals developed broad cross-genotype blockade, but this response was established before the second outbreak. Finally, we applied a novel competitive carbohydrate-blocking assay to demonstrate the epitope specificity and discrete compartments of the neutralizing response. Conclusions: Our data show that infection generates narrow, focused immunity directed toward the infecting genotype. We did detect broad cross-blocking in specific individuals, but these responses could be attributed to diverse, genotype-specific antibodies predating GII.6 infection.
- 21 February 2024
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 230 (4) , 982-994
Open AccessAnalysis of Archival Sera From Norovirus-Infected Individuals Demonstrates That Cross-Blocking of Emerging Viruses Is Genotype-Specific
Background: Rapidly evolving RNA viruses, such as human norovirus, generate extraordinary sequence diversity, posing a significant challenge to vaccine design. This diversity, coupled with short-lasting natural immunity, leads to reinfection throughout one's lifetime. How reexposure shapes humoral immunity to future norovirus strains remains incompletely understood. Methods: We profiled the antibody responses following 2 community gastroenteritis outbreaks with GII.2 and GII.6 noroviruses in 1971. Using diverse virus-like particles (VLPs), enzyme-linked immunosorbent assay (ELISA), and carbohydrate-blocking assays (surrogate for neutralization), we examined the antibody response at acute and convalescent timepoints following GII.6 infection. Results: Convalescent sera displayed strong homologous blocking, demonstrating a 5-fold increase in GII.6 carbohydrate blockade over acute samples, and broad blocking of diverse archival and modern GII.6 noroviruses. Convalescent sera displayed limited carbohydrate blocking of heterotypic VLPs, despite high ELISA binding titers. Select individuals developed broad cross-genotype blockade, but this response was established before the second outbreak. Finally, we applied a novel competitive carbohydrate-blocking assay to demonstrate the epitope specificity and discrete compartments of the neutralizing response. Conclusions: Our data show that infection generates narrow, focused immunity directed toward the infecting genotype. We did detect broad cross-blocking in specific individuals, but these responses could be attributed to diverse, genotype-specific antibodies predating GII.6 infection.
- Top Cited PapersOpen Access
- 28 April 2022
- Published by Wiley in Reviews in Medical Virology
- Vol. 32 (5) , e2354
Global and regional circulation trends of norovirus genotypes and recombinants, 1995–2019: A comprehensive review of sequences from public databases
Human noroviruses are the leading global cause of viral gastroenteritis. Attempts at developing effective vaccines and treatments against norovirus disease have been stymied by the extreme genetic diversity and rapid geographic distribution of these viruses. The emergence and replacement of predominantly circulating norovirus genotypes has primarily been attributed to mutations on the VP1 capsid protein leading to genetic drift, and more recently to recombination events between the ORF1/ORF2 junction. However, large‐scale research into the historical and geographic distribution of recombinant norovirus strains has been limited in the literature. We performed a comprehensive historical analysis on 30,810 human norovirus sequences submitted to public databases between the years 1995 and 2019. During this time, 37 capsid genotypes and 56 polymerase types were detected across 90 different countries, and 97 unique recombinant genomes were also identified. GII.4, both capsid and polymerase, was the predominately circulating type worldwide for the majority of this time span, save for a brief swell of GII.17 and GII.2 capsid genotypes and a near‐total eclipse by GII.P16, GII.P21 and GII.P31 beginning in 2013. Interestingly, an analysis of 4067 recombinants found that 50.2% (N = 2039) of all recorded sequences belonged to three recently emerged recombinant strains: GII.2[P16], GII.4[P31], and GII.4[P16]. This analysis should provide an important historical foundation for future studies that evaluate the emergence and distribution of noroviruses, as well as the design of cross‐protective vaccines.
- 28 April 2022
- Published by Wiley in Reviews in Medical Virology
- Vol. 32 (5) , e2354
Top Cited PapersOpen AccessGlobal and regional circulation trends of norovirus genotypes and recombinants, 1995–2019: A comprehensive review of sequences from public databases
Human noroviruses are the leading global cause of viral gastroenteritis. Attempts at developing effective vaccines and treatments against norovirus disease have been stymied by the extreme genetic diversity and rapid geographic distribution of these viruses. The emergence and replacement of predominantly circulating norovirus genotypes has primarily been attributed to mutations on the VP1 capsid protein leading to genetic drift, and more recently to recombination events between the ORF1/ORF2 junction. However, large‐scale research into the historical and geographic distribution of recombinant norovirus strains has been limited in the literature. We performed a comprehensive historical analysis on 30,810 human norovirus sequences submitted to public databases between the years 1995 and 2019. During this time, 37 capsid genotypes and 56 polymerase types were detected across 90 different countries, and 97 unique recombinant genomes were also identified. GII.4, both capsid and polymerase, was the predominately circulating type worldwide for the majority of this time span, save for a brief swell of GII.17 and GII.2 capsid genotypes and a near‐total eclipse by GII.P16, GII.P21 and GII.P31 beginning in 2013. Interestingly, an analysis of 4067 recombinants found that 50.2% (N = 2039) of all recorded sequences belonged to three recently emerged recombinant strains: GII.2[P16], GII.4[P31], and GII.4[P16]. This analysis should provide an important historical foundation for future studies that evaluate the emergence and distribution of noroviruses, as well as the design of cross‐protective vaccines.
- Open Access
- 8 March 2021
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 118 (11)
Antigenic cartography reveals complexities of genetic determinants that lead to antigenic differences among pandemic GII.4 noroviruses
Significance: The GII.4 genotype of human noroviruses accounts for the majority of gastroenteritis outbreaks worldwide. This predominance is characterized by the chronological emergence of new variants in response to immune pressure. We performed a comprehensive analysis on a large panel of GII.4 viruses to investigate the genetic determinants of antigenic diversification. Using immunoassays and neutralization data, we observed major changes to antigenic properties over the course of GII.4 evolution and increased intervariant cross-reactivity across contemporary viruses. Antigenic cartography and sequence analyses indicated a minimum number of coevolving amino acid changes on the structural protein necessary for the emergence of antigenically distinct variants. These insights could facilitate the monitoring and characterization of emerging GII.4 noroviruses and the development of cross-protective vaccines.
- 8 March 2021
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 118 (11)
Open AccessAntigenic cartography reveals complexities of genetic determinants that lead to antigenic differences among pandemic GII.4 noroviruses
Significance: The GII.4 genotype of human noroviruses accounts for the majority of gastroenteritis outbreaks worldwide. This predominance is characterized by the chronological emergence of new variants in response to immune pressure. We performed a comprehensive analysis on a large panel of GII.4 viruses to investigate the genetic determinants of antigenic diversification. Using immunoassays and neutralization data, we observed major changes to antigenic properties over the course of GII.4 evolution and increased intervariant cross-reactivity across contemporary viruses. Antigenic cartography and sequence analyses indicated a minimum number of coevolving amino acid changes on the structural protein necessary for the emergence of antigenically distinct variants. These insights could facilitate the monitoring and characterization of emerging GII.4 noroviruses and the development of cross-protective vaccines.